<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37748921</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2515-4478</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ evidence-based medicine</Title><ISOAbbreviation>BMJ Evid Based Med</ISOAbbreviation></Journal><ArticleTitle>How methodological pitfalls have created widespread misunderstanding about long COVID.</ArticleTitle><Pagination><StartPage>142</StartPage><EndPage>146</EndPage><MedlinePgn>142-146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjebm-2023-112338</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xf8;eg</LastName><ForeName>Tracy Beth</ForeName><Initials>TB</Initials><Identifier Source="ORCID">0000-0002-2341-6573</Identifier><AffiliationInfo><Affiliation>Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladhani</LastName><ForeName>Shamez</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0856-2476</Identifier><AffiliationInfo><Affiliation>Public Health England, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St George's University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6110-8221</Identifier><AffiliationInfo><Affiliation>Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA vinayak.prasad@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Evid Based Med</MedlineTA><NlmUniqueID>101719009</NlmUniqueID><ISSNLinking>2515-446X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">infectious disease medicine</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">virus diseases</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37748921</ArticleId><ArticleId IdType="pmc">PMC11137465</ArticleId><ArticleId IdType="doi">10.1136/bmjebm-2023-112338</ArticleId><ArticleId IdType="pii">bmjebm-2023-112338</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention (CDC) . Nearly one in five American adults who have had COVID-19 still have long Covid. 2022. Available: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm [Accessed 5 May 2023].</Citation></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med 2021;27:1129&#x2013;30. 10.1038/s41591-021-01402-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01402-w</ArticleId><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslam A, Olivier T, Prasad V. The definition of long COVID used in interventional studies. Eur J Clin Invest 2023:e13989. 10.1111/eci.13989</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13989</ArticleId><ArticleId IdType="pubmed">36964995</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Wiernik E, Robineau O, et al. . Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2022;182:19&#x2013;25. 10.1001/jamainternmed.2021.6454</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021;27:626&#x2013;31. 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long Covid outcomes at one year after mild SARS-Cov-2 infection: nationwide cohort study. BMJ 2023;380:e072529. 10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, et al. . Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021;18:e1003773. 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. . The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 2023;55:101762. 10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. . Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep 2022;12:9950. 10.1038/s41598-022-13495-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco JVA, Garegnani LI, Oltra GV, et al. . Short and long-term wellbeing of children following SARS-Cov-2 infection: a systematic review. Int J Environ Res Public Health 2022;19:14392. 10.3390/ijerph192114392</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192114392</ArticleId><ArticleId IdType="pmc">PMC9657555</ArticleId><ArticleId IdType="pubmed">36361269</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar J, Havdal LB, Drevvatne M, et al. . Prevalence and characteristics associated with post&#x2013;COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Netw Open 2023;6:e235763. 10.1001/jamanetworkopen.2023.5763</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5763</ArticleId><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. . Post-COVID conditions among adult COVID-19 survivors aged 18-64 and &gt;65 years &#x2013; United States, March 2020-November 2021. MMWR Morb Mortal Wkly Rep 2022;71:713&#x2013;7. 10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId><ArticleId IdType="pmc">PMC9368731</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594:259&#x2013;64. 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Vetter P, Chappuis F, et al. . Prevalence of post-COVID condition 12 weeks after Omicron infection compared to negative controls and association with vaccination status. Clin Infect Dis 2023;76:1567&#x2013;75. 10.1093/cid/ciac947</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac947</ArticleId><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, et al. . Burden of post-COVID-19 syndrome and implications for Healthcare service planning: a population-based cohort study. PLoS One 2021;16:e0254523. 10.1371/journal.pone.0254523</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke T, Ulyte A, Puhan MA, et al. . Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA 2021;326:869&#x2013;71. 10.1001/jama.2021.11880</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11880</ArticleId><ArticleId IdType="pmc">PMC8283661</ArticleId><ArticleId IdType="pubmed">34264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Follmann D, Janes HE, Buhule OD, et al. . Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med 2022;175:1258&#x2013;65. 10.7326/M22-1300</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-1300</ArticleId><ArticleId IdType="pmc">PMC9258784</ArticleId><ArticleId IdType="pubmed">35785530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallais F, Gantner P, Bruel T, et al. . Evolution of antibody responses up to 13 months after SARS-Cov-2 infection and risk of reinfection. EBioMedicine 2021;71:103561. 10.1016/j.ebiom.2021.103561</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103561</ArticleId><ArticleId IdType="pmc">PMC8390300</ArticleId><ArticleId IdType="pubmed">34455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, et al. . Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ 2023;381:e074425. 10.1136/bmj-2022-074425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074425</ArticleId><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>West EA, Anker D, Amati R, et al. . Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health 2020;65:1529&#x2013;48. 10.1007/s00038-020-01494-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00038-020-01494-0</ArticleId><ArticleId IdType="pmc">PMC7584867</ArticleId><ArticleId IdType="pubmed">33098441</ArticleId></ArticleIdList></Reference><Reference><Citation>
Swiss School of Public Health (SSPH+) . Corona immunitas. Available: https://www.corona-immunitas.ch/en [Accessed 2 Jul 2023].</Citation></Reference><Reference><Citation>
Office for National Statistics (ONS) . ONS Website, statistical bulletin, prevalence of ongoing symptoms following Coronavirus (COVID-19 infection in the UK). 2023. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023 [Accessed 16 May 2023].</Citation></Reference><Reference><Citation>
Office of National Statistics . Technical article: updated estimates of the prevalence of postacute symptoms among people with Coronavirus (COVID-19 in the UK). 2020. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021 [Accessed 15 Dec 2022].</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with Delta versus Omicron variants of SARS-Cov-2. Lancet 2022;399:2263&#x2013;4. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . What is long COVID?
Available: https://www.covid.gov/longcovid/definitions [Accessed 17 Jan 2023].</Citation></Reference><Reference><Citation>
WHO . Post COVID-19 condition (long Covid). n.d.
Available: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=It%20is%20defined%20as%20the,months%20with%20no no%20other%20explanation
</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners (RCGP) . COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742#:~:text=In%20addition%20to%20the%20clinical [Accessed 17 Jan 2023].</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>